Your browser doesn't support javascript.
Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization.
Engelen, Matthias M; Vandenbriele, Christophe; Balthazar, Tim; Claeys, Eveline; Gunst, Jan; Guler, Ipek; Jacquemin, Marc; Janssens, Stefan; Lorent, Natalie; Liesenborghs, Laurens; Peerlinck, Kathelijne; Pieters, Griet; Rex, Steffen; Sinonquel, Pieter; Van der Linden, Lorenz; Van Laer, Christine; Vos, Robin; Wauters, Joost; Wilmer, Alexander; Verhamme, Peter; Vanassche, Thomas.
  • Engelen MM; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Vandenbriele C; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Balthazar T; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Claeys E; Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Gunst J; Clinical Department and Laboratory of Intensive Care Medicine, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Guler I; Leuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat), KU Leuven, Leuven, Belgium.
  • Jacquemin M; Department of Cardiovascular Diseases and Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Janssens S; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Lorent N; Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Liesenborghs L; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Peerlinck K; The Outbreak Research Team, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
  • Pieters G; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Rex S; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.
  • Sinonquel P; Department of Anesthesiology, University Hospitals Leuven, Leuven, Belgium.
  • Van der Linden L; Department of Cardiovascular Diseases, KU Leuven, Leuven, Belgium.
  • Van Laer C; Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Vos R; Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.
  • Wauters J; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Wilmer A; Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Verhamme P; Department of CHROMETA, Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), KU Leuven, Leuven, Belgium.
  • Vanassche T; Medical Intensive Care, University Hospitals Leuven, Leuven, Belgium.
Semin Thromb Hemost ; 47(4): 362-371, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1203471
ABSTRACT

BACKGROUND:

Venous thromboembolism (VTE) is a frequent complication of COVID-19, so that the importance of adequate in-hospital thromboprophylaxis in patients hospitalized with COVID-19 is well established. However, the incidence of VTE after discharge and whether postdischarge thromboprophylaxis is beneficial and safe are unclear. In this prospective observational single-center study, we report the incidence of VTE 6 weeks after hospitalization and the use of postdischarge thromboprophylaxis.

METHODS:

Patients hospitalized with confirmed COVID-19 were invited to a multidisciplinary follow-up clinic 6 weeks after discharge. D-dimer and C-reactive protein were measured, and all patients were screened for deep vein thrombosis with venous duplex-ultrasound. Additionally, selected high-risk patients received computed tomography pulmonary angiogram or ventilation-perfusion (V/Q) scan to screen for incidental pulmonary embolism.

RESULTS:

Of 485 consecutive patients hospitalized from March through June 2020, 146 patients were analyzed, of which 39% had been admitted to the intensive care unit (ICU). Postdischarge thromboprophylaxis was prescribed in 28% of patients, but was used more frequently after ICU stay (61%) and in patients with higher maximal D-dimer and C-reactive protein levels during hospitalization. Six weeks after discharge, elevated D-dimer values were present in 32% of ward and 42% of ICU patients. Only one asymptomatic deep vein thrombosis (0.7%) and one symptomatic pulmonary embolism (0.7%) were diagnosed with systematic screening. No bleedings were reported.

CONCLUSION:

In patients who had been hospitalized with COVID-19, systematic screening for VTE 6 weeks after discharge revealed a low incidence of VTE. A strategy of selectively providing postdischarge thromboprophylaxis in high-risk patients seems safe and potentially effective.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Patient Discharge / C-Reactive Protein / Fibrin Fibrinogen Degradation Products / Venous Thromboembolism / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Systematic review/Meta Analysis Topics: Long Covid Limits: Humans / Male / Middle aged Language: English Journal: Semin Thromb Hemost Year: 2021 Document Type: Article Affiliation country: S-0041-1727284

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Patient Discharge / C-Reactive Protein / Fibrin Fibrinogen Degradation Products / Venous Thromboembolism / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Systematic review/Meta Analysis Topics: Long Covid Limits: Humans / Male / Middle aged Language: English Journal: Semin Thromb Hemost Year: 2021 Document Type: Article Affiliation country: S-0041-1727284